| Project/Area Number |
21590887
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Circulatory organs internal medicine
|
|---|
| Research Institution | Niigata University |
|---|
Principal Investigator |
TOBA Ken 新潟大学, 医歯学総合病院, 講師 (60313540)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
HANAWA Haruo 新潟大学, 医歯学系, 講師 (40282983)
OZAWA Takuya 新潟大学, 医歯学総合病院, 特任助教 (70467075)
|
|---|
| Project Period (FY) |
2009 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2011: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2010: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2009: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | 臨床心血管病態学 / 心血管系再生医学 / 循環器病態学 / 再生医療 / エリスロポエチン / アシアロエリスロポエチン / トランスレーショナル研究 / 新薬開発 |
|---|
| Research Abstract |
There have been technical and ethical problems for the application of cell therapy. Alternative medical such as cytokines other than cultured cells may help resolvingtheseproblems. Asialresourcesoerythropoietin(AEPO), a natural derivative of EPO, plays important role in angiogenesis and tissue protection of cardiovascular and central nervous systems. We started the preclinical studies on the in vitro and in vivo effects of AEPO. AEPO exerted strong cardiovasculoprotective and angiogenic activity in vivo. EPO derivatives expressed in vitro angiogenic activity in an intrinsic IL-6 dependent manner. AEPO showed tissue affinity in vitro and in vivo. We have entered into negotiations with a partner company for clinical applications of AEPO.
|
